Bristol-Myers Squibb Foundation's Together on Diabetes™ marks World Diabetes Day

Bristol-Myers SquibbThe Bristol-Myers Squibb Foundation has marked World Diabetes Day and the second anniversary of its Together on Diabetes™ initiative by issuing the initiative's second annual report and awarding two new grants to partners in India.

In its first two years, Together on Diabetes has awarded $43.2 million to 21 grantees working in 28 states and more than 50 communities in the United States. Since the expansion of the initiative to China and India in May 2012, $3.37 million has been awarded for seven projects in those countries. China, India and the U.S. have the most people living with diabetes.

"We are enormously proud of the work of our Together on Diabetes grantees and partners," said John Damonti, president, Bristol-Myers Squibb Foundation. "They are engendering hope in those hardest hit by the diabetes epidemic and transforming communities so that the healthy choice is an easier choice for the person living with type 2 diabetes."

Together on Diabetes' second annual report provides an update on the Foundation’s grantmaking and profiles how the innovative projects are helping people living with diabetes to improve control of their disease and how communities are coming together to make diabetes information and supportive services more visible, accessible, navigable, culturally competent and integrated with clinical care. The report also captures initial results and early lessons from the projects.

Two new Together on Diabetes grants in India support programs in Jodhpur and Mumbai:

  • Humana People to People will receive US $355,991 over two years to reduce diabetes-related morbidity and mortality and prevent the onset of type 2 diabetes among those at increased risk for the disease through timely intervention and home-based diabetes care.
  • United Way Mumbai Helpline will receive US $205,362 over two years to use community-based lifestyle interventions for the prevention, early detection and management of type 2 diabetes among working adults and municipal and public school workers in Mumbai.

About Together on Diabetes
Together on Diabetes is a five-year, $115 million initiative launched in November 2010 by the Bristol-Myers Squibb Foundation to improve health outcomes of people living with type 2 diabetes in China, India and the United States by strengthening patient self-management education, community-based supportive services and broad-based community mobilization. Consistent with the Bristol-Myers Squibb Foundation's mission to reduce health disparities, this initiative targets adult populations disproportionately affected by the disease.

About the Bristol-Myers Squibb Foundation
The Bristol-Myers Squibb Foundation is an independent 501(c)(3) charitable organization whose mission is to reduce health disparities and improve health outcomes around the world for patients disproportionately affected by serious disease.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Roche and Ignyta reach definitive merger agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta ...

Antidepressant may help combat the course of multi…

The antidepressant clomipramine may also alleviate symptoms of multiple sclerosis (MS), specifically in its progressive form, i.e. when it occurs without relapses or remi...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

FDA updates the label of Tasigna to reflect that c…

The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinu...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Sandoz regulatory submission for proposed biosimil…

Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics Licen...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

FDA approves first treatment for breast cancer wit…

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast can...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]